10-Q · August 7, 2025
Sonoma reported revenue of $4,015,000 for the quarter (up $624,000 or ~18% YoY) with gross profit of $1,464,000 and net loss of $1,241,000 (EPS $(0.76)). Operating loss improved to $(1,095,000) (operating margin -27.3%)…
Earnings analysis · 10-K
SNOA earnings analysis
Filed June 16, 2026 · Our reading of the company's report
The latest report
Sonoma Pharmaceuticals (SNOA) reported total revenue of $19.5 million for the fiscal year ending March 31, 2026, a 37% increase compared to $14.3 million in the previous year. The gross margin held steady at 38%, and…
Read full summary
Sonoma Pharmaceuticals (SNOA) reported total revenue of $19.5 million for the fiscal year ending March 31, 2026, a 37% increase compared to $14.3 million in the previous year. The gross margin held steady at 38%, and the net loss narrowed to $3.2 million, down from $3.5 million a year earlier. The company has faced ongoing operational challenges, and its future profitability hinges on successful collaborations and product commercialization in both domestic and international markets.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.89
- Gross margin
- 38%
- Segment
- Human Care
- Segment
- Animal Care
What stood out
-
Revenue Growth of 37%
Total revenue increased to $19.5 million in FY2026 from $14.3 million in FY2025.
-
Stable Gross Margin
Gross margin remained consistent at 38% for both FY2025 and FY2026.
-
Narrowed Net Loss
Net loss reduced to $3.2 million in FY2026 from $3.5 million in FY2025.
-
Increased U.S. Sales
U.S. revenue grew to $5.7 million, up 117% year-over-year from $2.6 million.
-
Strong International Performance
Revenue from Rest of World increased 92%, contributing to overall growth.
-
Successful Capital Raise
In April 2026, SNOA raised $3.5 million from a public offering, enhancing liquidity.
What to watch
-
Dependency on Key Customers
For FY2026, Customer C accounted for 15% of net revenues, indicating reliance on a few key customers.
-
High Intercompany Debt
The Mexican subsidiary owes approximately $12.3 million in principal with potential tax liabilities exceeding $16.5 million.
-
Regulatory Approval Risks
Future product approvals depend on compliance with varying international regulations, which are costly and time-consuming.
Management's outlook
Annual outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · November 7, 2024
Sonoma reported quarterly revenue of $3,579,000 (up from $2,731,000 a year earlier, +$848,000) and improved operating results: gross profit was $1,361,000 and loss from operations narrowed to $(850,000) from…
10-K · June 17, 2024
Sonoma positions itself as a specialist developer and manufacturer of stabilized hypochlorous acid (HOCl) products across dermatology, wound care, eye/oral/nasal care, podiatry, animal health and surface disinfectants,…
10-Q · February 8, 2024
Sonoma reported quarterly revenue of $3,138,000 (up from $2,944,000 year‑ago) with gross profit of $1,460,000 and a substantially narrower operating loss of $(844,000) vs $(1,834,000) prior year. Net loss improved to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.